MedTrace Logo

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor

NCT02444390 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-09-21

No results posted yet for this study

Summary

This is a prospective biomarker study to show that p4EBP1 staining predicts clinical benefit from treatment with everolimus in patients who are eligible for everolimus+exemestane treatment. This trial is not aimed at evaluating a drug activity. Everolimus and exemestane are prescribed within their approved indication as per usual practice and are not part of this trial.

Conditions

Interventions

PROCEDURE

Biopsy

biopsy of a metastasis

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Fondation ARC

    collaborator OTHER

  • UNICANCER

    lead OTHER

Principal Investigators

  • Thomas Bachelot, MD · Centre Léon Bérard, Lyon, France

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-19
Primary Completion
2018-10-31
Completion
2022-07-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02444390 on ClinicalTrials.gov